Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Select amongst our broad range of solutions and experience.
ICON leads portfolio transition of growth & non-growth products
A sponsor hired ICON to perform global regulatory affairs services (e.g., regional leads, CMC, labelling, publishing, and
submission management) for a recently acquired portfolio of registered products.
submission management) for a recently acquired portfolio of registered products.
Strategic blended solutions for enterprise efficiency
A top 20 pharma partner adopted a blended model of FSO, FSP, Stand-alone and specialty services to minimise operational costs whilst retaining control and increasing flexibility.
Examining approved adult drugs for kidney disease in children
A pharmaceutical company faced significant delays in its pediatric program, particularly in recruiting younger age groups, putting the study at risk. After missing multiple deadlines, the sponsor turned to ICON’s Centre for Paediatric Clinical Development for a strategic review, which resolved recruitment challenges and aligned the program with U.S. and European regulatory guidance.
.jpg?crop=yes&w=1979&h=1041&a=0,140&itok=ZEDGkWMN "Board meeting for device transition"){kind=icon}
FSP for a mid-sized device company
A mid-sized medical device company, required a smooth transition from using a staffing company alongside a full-service model, to an FSP model.
Regulatory resourcing solution for year-on-year success
A large scale regulatory resourcing solution was put in place for our client, including the transition of over 275 staff.
Driving high quality in global clinical drug development
A China-based biotech required an FSP model to grow team to 130 resources and increase retention to 85% in a highly competitive market.
Elevating Biopharma R&D
A biopharma partner required support with an FSP model across multiple service areas, seamlessly integrated with an existing FSO partnership.
Transforming a partnership into a blended model
A 10-year existing FSO partnership was expanded to incorporate a blended model to aid sourcing niche roles across multiple geographies whilst the sponsor maintained greater control of key areas.
Success in early phase psoriasis study
A randomised, double-blind, placebo-controlled study on behalf of a biotechnology organisation to evaluate the safety, tolerability, and efficacy of the study drug in subjects with moderate to severe plaque psoriasis.
High-volume medical imaging to support a MASH clinical trial
A pivotal phase 3 randomised, double-blind study to improve MASH and reduce progression to cirrhosis and/or hepatic decompensation, with high volumes of scans across two imaging modalities.
Phase 3 Multiple Myeloma study
A large-pharma sponsor was looking for a medical imaging partner to support a four-year, phase 3 Multiple Myeloma study. This trial included 600 patients and 200 sites and required expedited start-up and turnaround times.
Phase 3 unresectable biliary tract carcinoma study
A large pharmaceutical sponsor required an accelerated medical imaging data delivery for regulatory submission on a phase 3 advanced and/or unresectable biliary tract carcinoma study that spanned 277 sites with 1,115 patients.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.